After Hours Most Active GV.PA Genomic Vision SA: €0.0018 on 38.49M shares signals liquidity

GV.PA stock opened after hours at €0.0018 on 18 Mar 2026 and attracted heavy trading with 38,489,238 shares changing hands. This surge makes Genomic Vision SA (GV.PA) one of the most active names on EURONEXT in the after-hours session. The move follows thin liquidity, a very low market cap of €693,191, and a wide gap between the current price and the 50-day average of €0.00484 and 200-day average of €0.013997. We look at what drove volume, where valuations stand, and how models and analysts frame near-term price targets for GV.PA stock.

After-hours activity and price action for GV.PA stock

GV.PA stock traded between €0.0015 and €0.0020 today, closing the regular session at €0.0018 and up 5.88% intraday. The volume spike to 38,489,238 shares is 2.71x the average volume of 14,217,513, which indicates a liquidity event rather than broad institutional accumulation. Low floats and micro market cap mean even small order flows move price materially.

Investors should link the volume burst to short-term trading dynamics. With a year high of €0.094 and year low of €0.0014, the stock still sits near its multi‑year lows on EURONEXT in Europe.

Company fundamentals and sector context for GV.PA stock

Genomic Vision SA operates in Healthcare, specifically Medical – Diagnostics & Research, offering the FiberVision molecular combing platform and related kits and services. Revenue per share is €0.01085 and EPS is -€0.11, reflecting ongoing losses. The company lists strategic ties with Quest Diagnostics and research agreements with Institut Pasteur and La Timone Hospital, which support product validation and market access; see the company site for details Genomic Vision site.

Relative to the broader Healthcare sector on European exchanges, Genomic Vision shows weaker liquidity and negative profitability metrics. Sector averages show positive net margins and stronger ROE, so GV.PA stock is structurally higher risk within the Medical – Diagnostics & Research industry.

Valuation and key metrics shaping GV.PA stock analysis

Market metrics show a market cap €693,191, negative PE (reported -0.01636) and price-to-sales 0.47, indicating the share price is tiny relative to trailing sales per share. Cash per share is €0.00557 while book value per share is negative €-0.00944, signaling balance sheet stress and shareholder equity deficits. Current ratio is 0.91, below standard comfort levels.

Operational ratios highlight long working capital cycles: days sales outstanding 100.13, days of inventory on hand 2452.73, and days payable 2149.44, which reflect the company’s product and service model but also strain cash conversion. These metrics help explain why price averages (50-day €0.00484, 200-day €0.013997) remain materially above today’s price.

Meyka AI grade and technical outlook for GV.PA stock

Meyka AI rates GV.PA with a score out of 100: 62.5803 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects elevated volatility and modest upside potential against significant balance-sheet and cash-flow risks.

Technical indicators show price well below moving averages, which increases downside sensitivity. Traders should watch support near €0.0014 (year low) and immediate resistance at €0.0020 and the 50-day average €0.00484 for early trend confirmation.

Meyka AI forecast and price target scenarios for GV.PA stock

Meyka AI’s forecast model projects a base-case near-term price of €0.0025, a conservative upside of +38.89% from the current €0.0018, and a bull scenario price target of €0.0100 (+455.56%). A bear scenario places a downside target at €0.0010 (-44.44%). Forecasts are model-based projections and not guarantees.

These price targets reflect micro‑cap volatility, balance-sheet constraints, and product development milestones. Any material updates from partners or sales traction for FiberVision would be the most likely catalyst to push the stock toward the bull case.

Risk drivers, catalysts, and trading strategy for GV.PA stock

Primary risks include low liquidity, negative EPS (-€0.11), a thin market cap, and elongated cash conversion cycles that could require additional financing. A limited institutional presence raises execution risk on large orders. Sector headwinds or disappointing product validation would weigh heavily on valuation.

Key catalysts to monitor are new commercial contracts, published validation studies, updates from Quest Diagnostics collaborations, and any capital raises. For most active traders, strategies that size position for high volatility and set tight risk controls are essential when trading GV.PA stock on EURONEXT.

Final Thoughts

GV.PA stock is trading as one of the most active small-cap names after hours on EURONEXT today at €0.0018 with 38,489,238 shares traded. The volume spike highlights micro-cap liquidity dynamics rather than a clear fundamental re-rating. Financials show negative EPS at -€0.11, negative book value per share, and stressed working capital metrics. Meyka AI rates GV.PA with a score out of 100: 62.5803 | Grade: B | Suggestion: HOLD, a summary that balances product potential against cash and execution risk. Our model projects a base-case target of €0.0025 (+38.89%) and a bull target of €0.0100 (+455.56%), while a downside test could reach €0.0010 (-44.44%). Forecasts are model-based projections and not guarantees. Active traders should prioritise position sizing, clear stop levels, and catalyst-driven entries; longer-term investors must watch quarterly cash burn and any dilutive financing. For real-time monitoring and additional metrics, use Meyka AI’s AI-powered market analysis platform and the company site for corporate disclosures Genomic Vision site. For macro or market headlines that can shift sentiment, refer to premium news coverage such as the Wall Street Journal WSJ report.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.